The authors prove the concept that an anti-TCR Cb1 CAR cell based on the epitope of Jovi-1 anti-TCR Cb1 mAb can kill malignant T cell leukemic cells without destroying TCR Cb2 cells.
”Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.” Paul M Maciocia, Martin A Pule, et al. (2017) Nature Medicine 23: 1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13. PMID: 29131157